Po203 / #915 longitudinal data from the targeted drug delivery (tdd) product surveillance registry: pump pocket location

TDD with programmable intrathecal drug delivery systems (IDDS) has been approved for cancer and noncancer pain treatment since 1991 and severe spasticity since 1992. Early clinical IDDS studies specified an “abdominal pocket” as the pump implant location, resulting in this as the defined on-label location. Alternate pump implant locations are often necessary for patient-specific reasons, but full evaluation of the risks and benefits of these alternate pump sites has not been performed. Presented here is an evaluation of real-world registry data on the potential risks and benefits of alternate pump implant locations.